STOCK TITAN

Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Alumis (Nasdaq: ALMS) reported a narrower third-quarter 2026 net loss while advancing envudeucitinib toward a psoriasis regulatory submission. Net loss was $94.9 million, versus $110.8 million a year earlier; collaboration revenue declined to $1.9 million from $2.1 million. Research and development expenses fell to $80.8 million from $97.8 million. Cash, cash equivalents and marketable securities totaled $431.3 million at September 30, 2026; Alumis expects funding to last into fourth-quarter 2027.

Psoriasis data included 54% complete skin clearance at Week 48. Alumis remains on track for a fourth-quarter 2026 FDA application. The LUMUS lupus trial missed its primary and secondary endpoints overall, although responses were observed in a prespecified high-interferon subgroup. Alumis plans regulatory discussions and evaluation of development options, plus a Phase 2 Parkinson’s biomarker trial of A-005 in 2027.

Loading...
Loading translation...
21 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 7 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointThird-quarter net loss narrowed to $94.9 million from $110.8 million a year earlier.
  • Moderate pointThird-quarter research and development expenses fell to $80.8 million from $97.8 million a year earlier.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Alumis expects $431.3 million in September 30, 2026 liquidity to fund operations and capital expenditures into fourth-quarter 2027.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Alumis remains on track for a psoriasis FDA application in fourth-quarter 2026.
  • Minor pointEnvudeucitinib achieved 54% PASI 100, meaning complete skin clearance, at Week 48 in psoriasis.
16 minor points
  • Minor pointONWARD3 scalp results showed over 80% maintained clear or almost clear scalp skin at 48 weeks.
  • Minor pointONWARD1/2 itch results showed approximately one-third achieved clinically meaningful improvement as early as Week 2.
  • Minor pointONWARD1/2 itch results showed about 40% achieved complete resolution and approximately 60% minimal or no itch by Week 16.
  • Minor pointONWARD3 itch results showed nearly 80% sustained clinically meaningful improvement through Week 48.
  • Minor pointONWARD1/2 quality-of-life results showed approximately 50% had minimal or no daily impact from psoriasis by Week 12.
  • Minor pointONWARD3 quality-of-life results showed more than 70% maintained minimal or no daily impact at 48 weeks.
  • Minor pointPatients switching from placebo or apremilast reached improvements comparable to continuous treatment at Week 48.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Alumis anticipates two-year Phase 2 safety data for envudeucitinib in psoriasis in fourth-quarter 2026.
  • Minor pointLUMUS prespecified high-interferon subgroup showed responses on the primary and key secondary endpoints.
  • Minor pointLUMUS demonstrated dose-dependent interferon-pathway suppression, maximal at 40 mg twice daily.
  • Minor pointEnvudeucitinib was well tolerated in LUMUS, with no new safety signals.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Alumis plans end-of-Phase 2 regulatory interactions and evaluation of lupus development options.
  • Minor pointA-005 Phase 1 results showed central nervous system penetration, maximal peripheral target inhibition and tolerability.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Alumis plans an A-005 Phase 2 Parkinson’s biomarker trial in 2027.
  • Minor pointNine-month research and development expenses fell to $247.669 million from $303.213 million a year earlier.
  • Minor pointNine-month general and administrative expenses fell to $62.157 million from $76.267 million a year earlier.

Negative

  • Major pointLUMUS Phase 2b missed primary and secondary endpoints in the overall lupus trial population.
  • Moderate pointNine-month revenue fell to $5.310 million from $22.121 million a year earlier.
  • Moderate pointNine-month net loss widened to $330.155 million from $150.394 million a year earlier.
  • Moderate pointNine-month intangible asset impairment loss was $41.824 million, versus none a year earlier. 4.9% of market cap
  • Minor pointAlumis said high-interferon patients were unexpectedly under-represented in LUMUS, reducing overall trial response rates.
2 minor points
  • Minor pointThird-quarter collaboration revenue declined to $1.9 million from $2.1 million a year earlier.
  • Minor pointThird-quarter general and administrative expenses rose to $20.2 million from $19.5 million a year earlier.

Key Figures

PASI 100 response rate: 54% Scalp clearance: Over 80% Clinically meaningful itch reduction: Approximately one-third +5 more
PASI 100 response rate
54%
Week 48
Scalp clearance
Over 80%
ONWARD3 patients maintained clear or almost clear scalp skin at 48 weeks
Clinically meaningful itch reduction
Approximately one-third
Achieved by Week 2 in ONWARD1/2
Cash, cash equivalents and marketable securities
$431.3 million
As of September 30, 2026
Cash runway
Into the fourth quarter of 2027
Company's current operating plan
Research and development expenses
$80.8 million
Q3 2026, compared with $97.8 million in Q3 2025
Net loss
$94.9 million
Q3 2026, compared with $110.8 million in Q3 2025
Collaboration revenue
$1.9 million
Q3 2026, compared with $2.1 million in Q3 2025

Previous Earnings Reports

1 past event · Latest: Aug 13
Same Type 1 event
  1. Aug 13

    Q2 earnings

    24h Move
    +3.7%

    Q2 report cited ONWARD3 PASI 90 and PASI 100 response rates of 75% and 54%.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

tyk2 inhibitor, pasi, bicla, pharmacodynamic, +1 more
5 terms
tyk2 inhibitor medical
"a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor"
A TYK2 inhibitor is a type of drug that blocks the TYK2 protein, a key messenger that helps immune cells talk to each other. By calming overactive immune signals, these drugs can reduce inflammation in conditions like psoriasis and other autoimmune diseases; think of it as turning down a noisy intercom system. Investors watch TYK2 inhibitors for their potential to win approvals, capture treatment markets, and affect a company’s revenue and risk profile.
pasi medical
"Psoriasis Area and Severity Index (PASI) 100 response rate"
PASI is the Psoriasis Area and Severity Index, a single number that combines how much of the body is covered by psoriasis and how severe the lesions are (redness, thickness and scaling). Think of it like measuring both the size and intensity of a stain on clothing — the higher the score, the worse the condition; drug trials report percent reductions in PASI to show effectiveness. Investors watch PASI results because larger, consistent improvements drive regulatory approvals, market uptake and revenue potential for therapies.
bicla medical
"British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA)"
BICLA is a composite clinical trial measure used to judge whether a patient with systemic lupus erythematosus (SLE) has meaningfully improved across multiple organs and symptoms; it builds on a detailed clinical scoring system to decide ‘responder’ status. Investors care because BICLA-derived results often determine whether a drug is seen as effective by regulators and physicians, which directly affects trial success, approval chances and commercial value—think of it as a multi-subject report card that decides if a treatment passes.
pharmacodynamic medical
"Pharmacodynamic data from LUMUS confirmed robust dose-dependent interferon-pathway target engagement"
Pharmacodynamic describes how a drug acts on the body — the biological effects it produces, how strong those effects are, and how long they last. For investors, pharmacodynamic data show whether a treatment actually works and at what dose, shaping expectations about a drug’s safety, effectiveness, regulatory success and market potential; think of it like testing how well a key turns a lock and whether it reliably opens the door.
new drug application regulatory
"submit its New Drug Application to the FDA"
A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

– New Phase 3 data demonstrated rapid and durable improvements in plaque psoriasis burden, adding to envudeucitinib's differentiated clinical profile, including the highest publicly reported Week 48 PASI 100 response rate among existing and investigational oral psoriasis therapies –

– Alumis remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque
psoriasis in 4Q 2026 –

– Announced topline results from the LUMUS Phase 2b trial for envudeucitinib in systemic lupus erythematosus (SLE) –

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for the quarter ended September 30, 2026, and highlighted recent business updates and upcoming milestones.

“Each additional readout from the ONWARD program has strengthened the consistent body of evidence supporting envudeucitinib’s highly competitive profile in moderate-to-severe plaque psoriasis,” said Martin Babler, President and Chief Executive Officer of Alumis. “The new data presented in October showed early and durable improvement across scalp disease severity, itch resolution, and quality of life measures, building on a 54% PASI 100 response rate observed at 48 weeks of treatment. Our fourth-quarter 2026 NDA submission remains on track.”

Third Quarter 2026 and Recent Highlights

Envudeucitinib: a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate-to-severe plaque psoriasis

  • New data presented at the 26th Annual Fall Clinical Dermatology Conference demonstrated early and durable improvements across scalp disease severity, itch resolution, and quality of life measures. These data build on envudeucitinib’s high-threshold skin clearance observed across the ONWARD program, including a 54% Psoriasis Area and Severity Index (PASI) 100 response rate at Week 48 (LINK TO PR).
  • High rate of scalp clearance: Over 80% of patients in ONWARD3 maintained clear or almost clear scalp skin (scalp-specific Physician Global Assessment [ss-PGA] 0/1) at 48 weeks.
  • Rapid, robust and sustained itch relief: In ONWARD1/2, approximately one-third of patients—including those with moderate-to-severe scalp disease (ss-PGA ≥3)—achieved clinically meaningful itch reduction (≥4-point NRS improvement) as early as Week 2. By Week 16, about 40% reached complete itch resolution (NRS 0) and approximately 60% reported minimal or no itch (NRS 0/1). In ONWARD3, nearly 80% of patients sustained clinically meaningful itch reduction through Week 48.
  • Early, durable quality-of-life improvements: Approximately 50% of patients in ONWARD1/2 achieved a Dermatology Life Quality Index (DLQI) score of 0 or 1 by Week 12, reflecting minimal to no impact of psoriasis on daily activities. In ONWARD3, more than 70% of patients maintained DLQI 0/1 at 48 weeks.
  • Rapid crossover convergence: Patients switching from placebo or apremilast achieved rapid improvements across primary and key secondary endpoints, comparable to those continuously treated at Week 48.
  • Alumis remains on track to submit its New Drug Application to the FDA for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026.

Envudeucitinib: Systemic Lupus Erythematosus (SLE)

  • Phase 2b LUMUS trial of envudeucitinib for the treatment of moderate-to-severe systemic lupus erythematosus (SLE) did not meet its primary and secondary endpoints in the overall trial population (LINK TO PR).
  • Robust clinical responses were observed in a prespecified subgroup analysis of patients with high interferon gene signature (IFNGS-high), including on the primary endpoint of British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) and key secondary endpoints of Cutaneous Lupus Erythematosus Disease Area and Severity Index 50 (CLASI-50), SLE Responder Index 4 (SRI-4), and Lupus Low Disease Activity State (LLDAS).
  • IFNGS-high patients represent the majority of moderate-to-severe SLE cases. In LUMUS, they were unexpectedly under-represented, reducing response rates in the overall trial population.
  • Pharmacodynamic data from LUMUS confirmed robust dose-dependent interferon-pathway target engagement, with maximal suppression at the highest dose, 40 mg twice daily.
  • Envudeucitinib was well tolerated in LUMUS, with no new safety signals.
  • Alumis plans to conduct end-of-Phase 2 regulatory interactions and evaluate development options.

TYK2 Franchise and Pipeline Update

  • Alumis plans to initiate a Phase 2 biomarker trial for A-005, its central nervous system (CNS) penetrant TYK2 inhibitor, in patients with Parkinson’s disease, in 2027. In a Phase 1 healthy volunteer study, A-005 was well-tolerated, achieved maximal target inhibition in the periphery, and demonstrated the ability to penetrate the CNS.

Anticipated Milestones

  • Envudeucitinib in Moderate-to-Severe Plaque Psoriasis
    • Long-term data: Phase 2, two-year safety data (4Q 2026).
    • NDA submission (4Q 2026).

  • A-005

    • Initiation of Phase 2 biomarker trial in Parkinson’s disease (2027).

Third Quarter 2026 Financial Results

  • As of September 30, 2026, Alumis had cash, cash equivalents and marketable securities of $431.3 million.
  • Revenue consisted of collaboration revenue of $1.9 million for the quarter ended September 30, 2026, compared to collaboration revenue of $2.1 million for the quarter ended September 30, 2025, related to the collaboration and licensing agreement with Kaken Pharmaceutical Co., Ltd.
  • Research and development expenses were $80.8 million for the quarter ended September 30, 2026, compared to $97.8 million for the quarter ended September 30, 2025. The decrease was primarily driven by lower clinical trial and contract research costs reflecting the progression of the envudeucitinib clinical program following completion of the pivotal Phase 3 ONWARD1 and ONWARD2 clinical trials in patients with moderate-to-severe plaque psoriasis, partially offset by an increase in clinical trial and contract research costs for the Phase 3 ONWARD3 clinical trial.
  • General and administrative expenses were $20.2 million for the quarter ended September 30, 2026, compared to $19.5 million for the quarter ended September 30, 2025. The increase was primarily attributable to costs related to launch preparation efforts and an increase in personnel-related expenses for the quarter ended September 30, 2026, partially offset by severance and transaction costs related to the merger with ACELYRIN, Inc. and legal costs in the quarter ended September 30, 2025.
  • Net loss was $94.9 million for the quarter ended September 30, 2026, compared to net loss of $110.8 million for the quarter ended September 30, 2025.

Financial Guidance

  • Based on the Company’s current operating plan, Alumis continues to anticipate that its existing cash, cash equivalents and marketable securities as of September 30, 2026 are sufficient to fund operating expenses and capital expenditure requirements into the fourth quarter of 2027.


About Alumis
Alumis is a late-stage biopharma company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases, such as Parkinson’s disease. In addition, the pipeline includes several preclinical programs identified through this precision approach. For more information, visit www.alumis.com or follow us on LinkedIn or X. 

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and similar expressions intended to identify forward-looking statements. All statements contained in this press release other than statements of historical fact are forward-looking statements, including without limitation statements regarding: Alumis’ plans and anticipated timing for submitting an NDA for envudeucitinib in the fourth quarter of 2026; the therapeutic potential of TYK2 inhibition across immune-mediated, neuroinflammatory and neurodegenerative diseases and the potential multi-indication opportunity for envudeucitinib; the advancement of Alumis’ clinical pipeline including its plans to commence a Phase 2 biomarker study for A-005; the timing and results of clinical data readouts in its ongoing clinical trials, including long-term safety data in moderate-to-severe plaque psoriasis (PsO); the differentiated clinical profile of envudeucitinib and its potential to be a leading oral therapy in PsO; implications of the LUMUS IFNGS-high subgroup results for further development of envudeucitinib in SLE and Alumis’ plans to engage regulators regarding Phase 3 development in SLE; Alumis’ expectations regarding the sufficiency of its cash, cash equivalents and marketable securities to fund its operating expenses and capital expenditure requirements, including its anticipated cash runway; and Alumis’ future plans, strategy, prospects and anticipated milestones, as well as the assumptions underlying any of the foregoing. Forward-looking statements are based on Alumis’ current expectations, estimates, assumptions and projections as of the date of this press release and are subject to significant risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such statements. Readers should not place undue reliance on these forward-looking statements, and are cautioned that actual results, timing, safety, efficacy, performance or events and circumstances may differ materially from those expressed or implied in Alumis’ forward-looking statements due to a variety of risks and uncertainties including, without limitation, whether regulatory authorities accept for filing Alumis’ planned NDA submission as well as determine that envudeucitinib demonstrates an acceptable safety and efficacy profile and grant regulatory approval in moderate-to-severe plaque psoriasis; the timing and results of clinical trials; Alumis’ ability to obtain regulatory approval of and ultimately commercialize its product candidates; changes in Alumis’ operating plans and capital requirements that could reduce its anticipated cash runway; Alumis’ ability to obtain sufficient additional funding when needed and continue as a going concern; and Alumis’ ability to obtain, maintain and enforce intellectual property protection for its programs and product candidates. Additional information regarding these and other risks and uncertainties is contained under the heading “Risk Factors” and elsewhere in Alumis’ filings with the Securities and Exchange Commission (SEC), including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and subsequent filings with the SEC. Alumis explicitly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.


ALUMIS INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
             
  Three Months Ended September 30,
  Nine Months Ended September 30,
 
(in thousands) 2026  2025  2026  2025 
Revenue:            
License revenue $—  $—  $—  $17,389 
Collaboration revenue  1,907   2,066   5,310   4,732 
Total revenue  1,907   2,066   5,310   22,121 
Operating expenses:            
Research and development expenses  80,792   97,836   247,669   303,213 
General and administrative expenses  20,191   19,522   62,157   76,267 
Intangible assets impairment loss  —   —   41,824   — 
Total operating expenses  100,983   117,358   351,650   379,480 
Loss from operations  (99,076)  (115,292)  (346,340)  (357,359)
Other income (expense):            
Gain on bargain purchase  —   —   —   187,907 
Interest income  4,304   4,594   14,601   10,633 
Other income (expenses), net  (109)  (54)  (173)  (136)
Total other income (expense), net  4,195   4,540   14,428   198,404 
Net loss before income taxes  (94,881)  (110,752)  (331,912)  (158,955)
Income tax benefit  —   —   1,757   8,561 
Net loss $(94,881) $(110,752) $(330,155) $(150,394)
Other comprehensive income (loss):            
Unrealized gain (loss) on marketable securities, net  (47)  212   (918)  194 
Total comprehensive loss $(94,928) $(110,540) $(331,073) $(150,200)


ALUMIS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
       
  September 30,  December 31,
(in thousands) 2026  2025 
Assets      
Current assets:      
Cash and cash equivalents $57,691  $89,670 
Restricted cash  —   82 
Marketable securities, current  373,647   218,831 
Research and development prepaid expenses  3,437   2,909 
Other prepaid expenses and current assets  7,815   6,740 
Total current assets  442,590   318,232 
Restricted cash, non-current  1,388   1,301 
Property and equipment, net  16,427   18,190 
Intangible assets  9,135   50,959 
Operating lease right-of-use assets, net  16,744   16,971 
Other assets, non-current  2,427   6,287 
Total assets $488,711  $411,940 
Liabilities and Stockholders’ Equity      
Current liabilities:      
Accounts payable $8,926  $10,106 
Research and development accrued expenses  40,243   34,781 
Other accrued expenses and current liabilities  18,331   22,303 
Deferred revenue, current  6,876   1,458 
Operating lease liabilities, current  5,029   4,670 
Total current liabilities  79,405   73,318 
Operating lease liabilities, non-current  30,277   32,244 
Deferred tax liability  384   2,140 
Deferred revenue, non-current  —   2,611 
Other liabilities, non-current  220   330 
Total liabilities  110,286   110,643 
Stockholders’ equity:      
Preferred stock  —   — 
Common stock  13   10 
Additional paid-in capital  1,611,173   1,202,975 
Accumulated other comprehensive income (loss)  (730)  188 
Accumulated deficit  (1,232,031)  (901,876)
Total stockholders’ equity  378,425   301,297 
Total liabilities and stockholders’ equity $488,711  $411,940 


Alumis Contact Information

Teri Dahlman
Red House Communications
teri@redhousecomms.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does Alumis plan to submit envudeucitinib for FDA approval in psoriasis?

Alumis remains on track to submit its New Drug Application in the fourth quarter of 2026 for envudeucitinib in moderate-to-severe plaque psoriasis. Two-year Phase 2 safety data are also anticipated in the fourth quarter of 2026.

Did Alumis’s LUMUS lupus trial meet its endpoints?

The Phase 2b LUMUS trial did not meet its primary and secondary endpoints in the overall population. A prespecified subgroup with a high interferon gene signature showed responses on the primary and key secondary endpoints. Alumis plans end-of-Phase 2 regulatory interactions and evaluation of development options.

Why did Alumis’s third-quarter 2026 research and development expenses decline?

Research and development expenses declined primarily because of lower clinical trial and contract research costs following completion of the pivotal ONWARD1 and ONWARD2 psoriasis trials. Increased clinical trial and contract research costs for ONWARD3 partially offset the decrease.

Keep reading